Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.85 |
| ▸ | MEN1 | O00255 | 9/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.78 |
| ▸ | RAB9A | P51151 | 8/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.78 |
| ▸ | NPC1 | O15118 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 6/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.78 |
| ▸ | HTT | P42858 | 4/20 | 0.78 |
| ▸ | NPY1R | P25929 | 1/20 | 0.78 |
| ▸ | ALPI | P09923 | 2/20 | 0.73 |
| ▸ | ALPG | P10696 | 2/20 | 0.73 |
| ▸ | CASP6 | P55212 | 2/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | NSD2 | O96028 | 1/20 | 0.73 |
| ▸ | CASP7 | P55210 | 1/20 | 0.73 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546094 | 0.83 | MAPT (0.68) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL30924972 | 0.82 | MEN1 (0.64) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL13694246 | 0.82 | MEN1 (0.77) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL29130866 | 0.81 | ALPL (0.59) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL18529266 | 0.80 | RAB9A (1.00) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL27766071 | 0.78 | ATG4B (0.71) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL1804666 | 0.78 | NPC1 (0.76) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL18424530 | 0.77 | ATG4B (0.69) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL881339 | 0.77 | LMNA (0.84) | ALPLMEN1KMT2ARAB9AMAPT | |
| SCHEMBL3466003 | 0.77 | LMNA (0.67) | ALPLMEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199523-A1 | Heterocyclic calcium in channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199523-A1 | Heterocyclic calcium in channel blockers | CACNA1C, CACNA1B, CACNA1D | ALPL 4519/4885MEN1 1836/4885KMT2A 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.